5050 Nathan Lane
175 articles about Abbott
Abbott's TriClip™ Becomes First Device of its Kind to Receive CE Mark for Minimally Invasive Tricuspid Valve Repair
Abbott (NYSE: ABT) today announced that its TriClip™ Transcatheter Tricuspid Valve Repair System has received CE Mark and is now approved for use in Europe and other countries that recognize CE Mark as a non-surgical treatment for people with a leaky tricuspid valve, a condition known as tricuspid regurgitation (TR).
Abbott's FreeStyle® Libre 14 Day System Now Available in U.S. for Hospitalized Patients with Diabetes During COVID-19 Pandemic
Abbott (NYSE: ABT) announced today that the FreeStyle Libre 14 day system, the world's leading3 continuous glucose monitoring (CGM) technology, can now be used in the hospital setting2 during the COVID-19 pandemic, according to the U.S. Food and Drug Administration (FDA)
Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minutes
Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes
The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 36 cents per share.
New Real-World Data Show that Abbott's FreeStyle Libre System Delivers Positive Health Outcomes for People with Type 1 and Type 2 Diabetes
Abbott (NYSE: ABT) announced today that four real-world data abstractsi,ii,iii,iv are being presented during the 13th Advanced Technologies & Treatments for Diabetes (ATTD) in Madrid.
Abbott Introduces Next-Generation Heart Rhythm Management Devices in Europe, Featuring State-of-the-Art Patient App and Bluetooth Connectivity
Abbott (NYSE: ABT) today announced it has received CE Mark for the new Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices, bringing the most advanced heart rhythm management capabilities along with a new set of benefits to people in Europe with abnormal heart rhythms and heart failure.
Abbott's In-Development Fully Implantable Heart Pump System Earns FDA's Breakthrough Device Designation
Abbott (NYSE: ABT) today announced that the company has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its in-development Fully Implantable Left Ventricular Assist System (FILVAS).
- The CATALYST trial will examine Abbott's Amplatzer™ Amulet™ device compared to non-vitamin K oral anticoagulants, the current standard in attempting to lower stroke and bleeding risks for patients with atrial fibrillation
Abbott (NYSE: ABT) today announced that its Tendyne™ Transcatheter Mitral Valve Implantation (TMVI) system received CE Mark and is now approved for use in Europe.
Abbott Receives Expanded Indication From the U.S. FDA for Directional Deep Brain Stimulation System to Treat Parkinson's Disease
Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for a new, expanded indication for the company's Infinity™ Deep Brain Stimulation (DBS) system to include targeting of an area of the brain called the internal globus pallidus (GPi).
Abbott (NYSE: ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2019.
New clinical trial will assess first-of-its-kind MitraClip™ transcatheter mitral valve repair against current standard of care surgery in a new, expanded patient population
FDA Approves Less Invasive Surgical Approach for Abbott's Heart Pump to Help Patients Avoid Open Heart Surgery
For people battling advanced heart failure, Abbott's HeartMate 3 heart pump can now be implanted through an incision in the chest wall versus open heart surgery
The board of directors of Abbott (NYSE: ABT) today increased the company's quarterly common dividend to 36 cents per share – a 12.5% increase.
Abbott Announces Robert B. Ford to Succeed Miles D. White as Chief Executive Officer on March 31, 2020
Abbott (NYSE: ABT) today announced that Miles D. White will be stepping down as Chief Executive Officer on March 31, 2020, after a remarkable 21-year tenure, the second longest for a non-founder in today's S&P 100. He will remain Executive Chairman of the Board.
Abbott Announces Discovery of New Strain of HIV, Keeping Global Health Community a Step Ahead of the Virus
Discovery marks the first time a new subtype of HIV-1 has been identified since 2000
The Australian Red Cross Blood Service Selects Abbott's Alinity s Solution for Blood and Plasma Screening
Abbott (NYSE: ABT) today announced the Australian Red Cross Blood Service (Australian Blood Service) has signed a multiple-year agreement for Abbott's most advanced blood and plasma screening technology, Alinity™ s System.
Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2019.
Abbott and Omada Health Partner to Offer Integrated Digital Health and Coaching Experience for People with Type 2 Diabetes
Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) technology, with Omada Health's pioneering digital care program, aiming to create a new paradigm for people with Type 2 diabetes
Late-Breaking Data Shows Abbott's MitraClip™ is Cost Effective, Increases Life Expectancy and Improves Quality of Life
New late-breaking data at TCT 2019 demonstrate that Abbott's MitraClip™ is cost-effective for heart failure patients with significant secondary mitral regurgitation compared to guideline-directed medical therapy alone